CVX Research Update — September 12, 2026 (Updated)
Updated Thesis
Chevron is a global integrated oil and gas major organized into Upstream and Downstream segments, spanning crude oil and natural gas exploration, LNG processing and transport, refining, petrochemicals, and lubricants, with 43,039 full-time employees and a market capitalization of $409.31 billion at a current price of $205.52. The business quality is high: it generates $13.71 of free cash flow per share and $104.8 of revenue per share, earns an 11.0% return on equity, and trades at 14.99 times free cash flow and 7.85 times EV/EBITDA, which are undemanding absolute multiples for an integrated major with a cost-advantage position and a structural cost-reduction program that had already delivered $3 billion of annual run-rate savings by the second quarter of 2026 against a $3-$4 billion target by year-end 2026. The most recent quarter showed 51.4% revenue growth and approximately 384.8% earnings growth, but those figures were flattered by elevated liquids realizations, $1.5 billion of favorable timing effects, and about $1.7 billion of downstream-margin uplift, so they should not be extrapolated.
The investment grade as of this refresh is B — solid business quality. B-tier business, B-tier valuation with 35.9% upside to blended fair value.
Grade Change
In this research cycle, the investment grade for Chevron Corporation moved from C to B. B-tier business, B-tier valuation with 35.9% upside to blended fair value.
Key Metrics at a Glance
- Revenue growth: +51.4% year over year
- Net margin: 9.9%
- Fair value upside: +35.9% to our estimate of $279
Current price: $205.52
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Chevron Corporation remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full CVX research →](/stocks/CVX)